W. E. Donoghue & Co. LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 121,854 shares of the company’s stock, valued at approximately $16,120,000. Johnson & Johnson comprises 1.8% of W. E. Donoghue & Co. LLC’s investment portfolio, making the stock its 23rd biggest holding.
A number of other hedge funds have also bought and sold shares of JNJ. State Street Corp increased its holdings in Johnson & Johnson by 4.3% during the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after purchasing an additional 6,656,371 shares during the last quarter. BlackRock Inc. increased its holdings in Johnson & Johnson by 2.6% during the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Johnson & Johnson by 717.9% during the 2nd quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock worth $495,837,000 after purchasing an additional 3,289,763 shares during the last quarter. Vanguard Group Inc. increased its holdings in Johnson & Johnson by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares during the last quarter. Finally, Parametric Portfolio Associates LLC increased its holdings in Johnson & Johnson by 47.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock worth $1,054,433,000 after purchasing an additional 2,581,562 shares during the last quarter. Institutional investors own 65.89% of the company’s stock.
Several research analysts have recently commented on JNJ shares. Cowen reiterated an “outperform” rating and issued a $155.00 target price (up previously from $147.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. UBS reiterated a “buy” rating and issued a $148.00 target price on shares of Johnson & Johnson in a research report on Thursday, August 31st. Jefferies Group lifted their target price on Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, October 16th. Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Finally, Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $145.04.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. During the same quarter in the previous year, the firm posted $1.68 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. equities analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were given a dividend of $0.84 per share. The ex-dividend date was Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a yield of 2.36%. Johnson & Johnson’s dividend payout ratio is currently 58.33%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.